About

About us

Chongde Seeks Truth and Achieves Customers

Company Profile

Innovative driven new drug non clinical research and development full industry chain characteristic service platform

Taichu Group was founded in October 2020 in the Life Blue Bay area of Lingang New Area. It is committed to providing global pharmaceutical companies with services such as non clinical drug evaluation (CRO), antibody drug construction and production (CRO/CDMO), chemical drug formulation research and production (CMC/CDMO), small nucleic acid development, pilot and commercial OEM production (CRO/CDMO/MAH).
The group has established a GLP/GMP quality system that meets international standards, and has a unique technical system at the international advanced level.

Overall layout

The main body of the company is located in the Lingang New Area of Shanghai, with a total area of 26200m ² Service facilities for
The antibody research and production base is located in BioBay, Suzhou, with an area of 8000m ² GMP factory facilities and laboratories

Corporate culture

Philosophy

Company Mission, Vision, and Values

Philosophy

Mission: To assist in the launch of new drugs and benefit patients
Vision: Create an empowering platform to achieve medical dreams
Values: Respecting morality and seeking truth, achieving customer success

01
Enterprise Spirit

Advocating quality, team writing, willing to contribute, and putting people first

Enterprise Spirit

Advocate for quality: Quality is the foundation of survival, and quality is the source of benefits
Unity and collaboration: Promote internal cooperation and encourage win-win cooperation within the organization
Willing to contribute: Integrate personal interests into collective interests, strive to contribute more to collective interests, and achieve personal interests at the same time
People oriented: Basic principles: Respect employees, motivate employees, and cultivate employees

02

Team

Jing Ma Ph.D.

Chairman and CSO of Taichu Group

Jing Ma Ph.D.

Chairman and CSO of Taichu Group

Ph.D. in Drug Toxicology; Doctoral Supervisors of China National Pharmaceutical Industry Research Institute, Fudan University and Shanghai Jiao Tong University

General Manager and Professor of Shanghai National Center for New Drug Safety Evaluation & Research (2006-2016); Founder and Chairman of the Board of Shanghai Innostar Biotechnology Co., Ltd, (2010-2019)

Expert in New Drug Review and GLP Inspection, National Medical Products Administration (NMPA); Member, ICH Working Group; Vice President, Chinese Society of Toxicology; Honorary Chair, Toxicology Specialty Committee, Chinese Pharmacological Society

Successfully passed three OECD GLP certifications and two FDA GLP inspections;

Publication of more than 150 article;

Established 51 new methods for drug toxicology research; more than 7,000 toxicological studies; >3,000 new drugs developed for companies in China and overseas; 34 first-class new molecules were approved for marketing; >100 new drugs were approved for clinical trials in the United States and other countries;

Participated in drafting/revising the GLP inspection standard in NMPA and 15 CDE safety guideline.

11 years of pharmacology experience and 29 years of combined pharmacology/toxicology teaching and research expertise; 18 years of GLP/CRO management experience in the pharmaceutical R&D sector.
Xun Liu Ph.D.

CEO of Taichu Group

Xun Liu Ph.D.

CEO of Taichu Group

Ph.D. from Rutgers University, USA;

Postdoctoral fellow at MIT. Studied under Nobel Prize Laureate Professor Gobind Khorana and completed three and a half years of postdoctoral research;

More than 30 years of experience in pharmaceutical industry;

Principal Engineer of Bayer Pharmaceuticals and Production Specialist for Bayer top-selling drug Kogenate®;

Tenured Research Scientist at Vaccine Research Center (National Institutes of Health)，responsible for process development, clinical and commercial manufacturing of therapeutic and prophylactic vaccines;

Vice President of Jiangsu Hengrui Pharmaceutical Co., Ltd. and President of Hengrui Pharmaceutical Biomedical Development Division since 2015. Commercial development of more than 50 new drugs, of which 27 had entered clinical trials and 5 products had been approved for marketing;

Chief Technical Officer of Overland Pharma;

Senior Advisor of Hillhouse Investment.
Jianliang Li Ph.D.

General Manager of AceMab

Jianliang Li Ph.D.

General Manager of AceMab

Graduated from the School of Life Sciences at Fudan University with a PhD in Embryonic Stem Cell Biology from Sheffield University;

Former senior scientist and project leader at GE Healthcare;

Former team leader and senior scientist in the biopharmaceutical new drug development department of AstraZeneca (UK);

Over 20 years of experience in cancer research, stem cell biology, and molecular biology research and development management;

The first inventor of a patent and the second inventor of a patent.
Hao Li Ph.D.

General Manager of Tarlead Biotechnology

Hao Li Ph.D.

General Manager of Tarlead Biotechnology

Senior Director of Shanghai Hengrui Pharmaceutical Co., Ltd.. Head of Process Development, Final Product Development, Analytical Method Development and Quality Characterization, Cell line New technology Development, ADC Development and Manufacturing Department

Responsible for CMC development of more than 50 new biological drugs, of which over 30 have successfully obtained approval for clinical trials, 2 products are under BLA review, and 3 products have been approved for marketing

13+ years of experience, especially on monoclonal antibody, bispecific antibody, fusion protein and ADC products

Member of CDE Guidelines Drafting Group on ADC Pharmaceutical Research

As project leader, undertaken Shanghai Academic Leaders Project in 2023
Jason Zhou Ph.D.

Senior Vice President of TJR Bio

Jason Zhou Ph.D.

Senior Vice President of TJR Bio

Ph.D. in Organic Chemistry from the University of South Florida, USA. Completed postdoctoral research at Texas A&M University under the mentorship of Prof. James Sacchettini.

Served as CMC Senior Director at Visirna, responsible for CMC activities of siRNA therapeutics including IND/NDA regulatory submissions for imported products, localized technical transfers, CMC development/scale-up of in-house pipelines, and clinical supply chain operations. Accumulatively completed 7 siRNA drug INDs, China’s first biotech-led siRNA pre-NDA/NDA submissions, and demonstrated in-depth understanding of FDA and NMPA pharmaceutical regulatory requirements and CMC/NDA study frameworks for oligonucleotide drugs.

Previously engaged in drug discovery at GSK US Pharmaceuticals, covering medicinal chemistry design and synthesis.

Led the Early-Stage Process R&D Department at STA Pharma (WuXi), directing teams to complete early-phase CMC process development for ~70 small molecule drugs.

Held CMC leadership roles at InnoCare Pharma and AnHeart, overseeing end-to-end CMC. Contributed to 18+ small molecule IND filings, 2 PPQ campaigns, and 1 approved NDA.

Accumulated 20+ years of experience in small molecule & siRNA innovative drugs across CMC development, CMC strategy and global regulatory filing.
Zhihua Zhang Ph.D.

Senior Toxicology Consultant

Zhihua Zhang Ph.D.

Senior Toxicology Consultant

Ph.D., Toxicology, Rutgers University/University of Medicine and Dentistry of New Jersey, Piscataway, NJ

As President, Ridge Pharma Consulting, LLC, NJ

Former Executive Vice President, Early Development and Project Management in Ark Biosciences, Inc., Shanghai

More than twenty-six years’ experience in pharmaceutical/biotech industry R&D strategic planning and execution

An expert intoxicology, pharmacology/animal efficacy models, DMPK / ADME, and early clinical development

Successful filings of more than thirty (25) INDs and five (5) NDAs in the US, four (4) MAAs in Europe, and multiple INDs in China and Australia

Served as the first president of American Association of Chinese in Toxicology and a board-certified toxicologist.

Group structure

Construction and Discovery Platform for Whole Human Antibodies

Taichu Biotechnology Biology

Innovative drug non clinical research and service platform

Tarlead Biology

CDMO platform for the development and production of antibody drug processes

End-to-end Service from Oligonucleotide R&D to drug product manufacturing

Taichu (Shenzhen)

Consulting Services&Business Activities

Investor Relations

As of August 2022, Taichu Biotechnology has completed the A-round financing, with a total financing amount of nearly 400 million yuan.

This round of financing is led by IDG Capital and recognized by well-known investment institutions in the industry.

Tel021-80403636

E-mailmarketing@taichubio.com

AddressNo. 308 Pingda Road, Lingang Special Area,Shanghai, China

AceMab Wechat official account

Taichu Biotechnology Wechat official account

Tarlead Wechat official account

TJR BIO Wechat official account

Taichu (Shenzhen) Wechat official account

Copyright ©2023 Taichu Group. All Rights Reserved沪ICP备2023012905号-1

Legal Notice丨 Website Map丨

Links

Baidu